Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12268073 | 1.00 | APP (1.00) | APPMAOB | |
| SCHEMBL1614417 | 1.00 | APP (1.00) | APPMAOB | |
| SCHEMBL18806907 | 0.92 | APP (1.00) | APPMAOB | |
| SCHEMBL18211386 | 0.86 | APP (0.76) | APPMAOB | |
| SCHEMBL1507879 | 0.86 | APP (0.76) | APPMAOB | |
| SCHEMBL12317126 | 0.85 | APP (0.74) | APPMAOB | |
| SCHEMBL1615276 | 0.83 | APP (1.00) | APPMAOB | |
| SCHEMBL18822149 | 0.82 | APP (0.70) | APPMAOB | |
| SCHEMBL1508028 | 0.81 | APP (0.69) | APP | |
| SCHEMBL1615317 | 0.81 | APP (0.68) | APPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651876-A1 | TARGETED THERANOSTIC AGENTS FOR IMAGING AND TREATING CANCER | The Board of Regents of the University of Texas System (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024211430-A2 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-115645389-B | Application of compound ML1 and derivative thereof in improving activity and function of cerebral cortex | 刘晓栋 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024155993-A1 | TARGETED THERANOSTIC AGENTS FOR IMAGING AND TREATING CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-25 | — | — | WO | disclosed |
| CN-118005611-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240009332-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-01-11 | — | — | US | disclosed |
| US-11851446-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230243811-A1 | IDENTIFICATION OF TRANSPLANTED HUMAN CELLS | RIGSHOSPITALET (REGH) (DK) | 2023-08-03 | — | — | US | disclosed |
| US-11712487-B2 | Composite embolization beads | RAIKA MEDICAL IMAGING INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115645389-A | Application of compound ML1 and derivatives thereof in improving activity and function of cerebral cortex | 刘晓栋 | 2023-01-31 | — | — | CN | disclosed |
| EP-3166610-B1 | METHODS FOR TREATING NEUROLOGIC DISORDERS | EIP PHARMA LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3368040-B1 | METHODS AND COMPOSITIONS FOR RECOVERY FROM STROKE | EIP PHARMA LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11344637-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11291670-B2 | Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis | PHARNEXT (FR) | 2022-04-05 | — | — | US | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851446-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, HSPBP1 | APP 270/4885MAOB 3619/4885 |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | APP 270/4885MAOB 3619/4885 |
| US-11344637-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | APP 270/4885MAOB 3619/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | APP 270/4885MAOB 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.